Israel's place in the global cannabis market is a study in contrasts: scientifically influential far beyond its size, yet a modest, import-dependent buyer in the world trade. This guide sets Israel against the major markets to show where it actually fits.
This guide is informational and is not investment advice. Figures are estimates and change.
Small market, outsized influence
In pure revenue terms, Israel is a minor market — roughly US$372 million in 2025 (Statista), a fraction of the large adult-use and medical markets elsewhere. But its influence on cannabis science and policy is disproportionate, rooted in a research legacy running from Raphael Mechoulam to today's institutions. Israel is watched as a testbed, not bought from as a supplier.
Versus Germany
Germany is the market Israeli companies chase. After loosening its rules, Germany has become Europe's largest medical cannabis market, consuming around 142 tonnes in 2025 (GrowerIQ). That demand is why operators like IM Cannabis built German businesses — German growth, not Israeli growth, has been the sector's engine. Israel, by contrast, has a plateauing patient base.
Versus Canada
Canada is the world's dominant exporter and Israel's main supplier. Canada exported around 240 tonnes of cannabis in 2025 (GrowerIQ), and supplies roughly 80% of Israel's imports. The relationship is lopsided: Israel is a customer, and cheaper Canadian flower is precisely what undercuts Israeli producers at home and abroad (see imports and supply).
Versus the United States
The US has enormous state-legal markets but remains federally prohibited, which fragments it and — importantly for Israel — has historically held back US research. That federal barrier is part of why Israel, with state permission and funding for cannabis science, captured a research lead the much larger US market could not. It is also the market IM Cannabis has signalled it may try to enter.
Where Israel actually fits
Put together: Israel is a small, medical-only, import-dependent market with a world-leading research and standards base. It does not compete on volume or low-cost production; it competes on credibility and science. For investors and operators, that means Israel matters less as a place to sell tonnes of flower and more as a source of clinical evidence, pharmaceutical-grade know-how and policy signals.
For the underlying numbers, see market size, patient numbers and imports and supply; the full overview is in our Market hub.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Market.